Ali Şahin
Research Subjects
Ali Şahin has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Mehmet Emin Derin
Department of Internal Medicine, Rheumatology Unit, Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey
3 shared publications - Neşe Çabuk Çelik
Department of Rheumatology, Sincan Training and Research Hospital, Ankara, Turkey
3 shared publications - Fatih Albayrak
Department of Rheumatology, Gaziantep University, 27310 Gaziantep, Turkey
2 shared publications - Halef Okan Doğan
Sivas Cumhuriyet Üniversitesi
2 shared publications - Mehtap Şahin
Sivas Cumhuriyet Üniversitesi
2 shared publications - Abdullah İlhan
Department of Internal Medicine, Faculty of Medicine, Cumhuriyet University, Sivas, Turkey
1 shared publication
Latest Publications
- 22 May 2026
- Published by Caleo in Rheumatology Quarterly
PREVALENCE OF INFLAMMATORY RHEUMATOLOGIC DIAGNOSES AMONG PATIENTS PRESENTING WITH JOINT PAIN: A RETROSPECTIVE COHORT STUDY
Objective: Joint pain is a frequent complaint in clinical practice, often affecting patients’ quality of life. Differentiating between inflammatory rheumatological diseases and non-inflammatory causes, such as osteoarthritis or fibromyalgia, is essential for proper management. This study aimed to evaluate the prevalence of inflammatory rheumatological diagnoses in patients presenting with joint pain and to assess their demographic characteristics. Methods: A retrospective observational study was conducted on 2732 patients who visited the rheumatology outpatient clinic between October 20, 2023, and August 20, 2025, and whose primary ICD-10 diagnosis was joint pain (M25.5). Only first-time visits were included. Secondary diagnoses were used to classify patients into 2 groups: inflammatory rheumatological and non-inflammatory rheumatological. Data were analyzed using Excel and IBM SPSS v25. The Mann–Whitney U-test and chi-square test were used for age and gender comparisons, respectively. Results: Of the patients, 29.4% (n=803) were diagnosed with inflammatory rheumatological diseases, while 70.6% (n=1.929) had non-inflammatory conditions. The mean age was 52.6 ± 13.3 years in the inflammatory group and 54.8 ± 12.9 years in the non-rheumatological group (P < .001). Female patients comprised 78% of the total population, with a significant gender difference between the 2 groups (P < .001). Conclusion: Nearly one-third of patients with joint pain referred to rheumatology received an inflammatory rheumatological diagnosis. These findings may inform clinical triage, improve early diagnosis, and contribute to more efficient healthcare utilization.
- 22 May 2026
- Published by Caleo in Rheumatology Quarterly
PREVALENCE OF INFLAMMATORY RHEUMATOLOGIC DIAGNOSES AMONG PATIENTS PRESENTING WITH JOINT PAIN: A RETROSPECTIVE COHORT STUDY
Objective: Joint pain is a frequent complaint in clinical practice, often affecting patients’ quality of life. Differentiating between inflammatory rheumatological diseases and non-inflammatory causes, such as osteoarthritis or fibromyalgia, is essential for proper management. This study aimed to evaluate the prevalence of inflammatory rheumatological diagnoses in patients presenting with joint pain and to assess their demographic characteristics. Methods: A retrospective observational study was conducted on 2732 patients who visited the rheumatology outpatient clinic between October 20, 2023, and August 20, 2025, and whose primary ICD-10 diagnosis was joint pain (M25.5). Only first-time visits were included. Secondary diagnoses were used to classify patients into 2 groups: inflammatory rheumatological and non-inflammatory rheumatological. Data were analyzed using Excel and IBM SPSS v25. The Mann–Whitney U-test and chi-square test were used for age and gender comparisons, respectively. Results: Of the patients, 29.4% (n=803) were diagnosed with inflammatory rheumatological diseases, while 70.6% (n=1.929) had non-inflammatory conditions. The mean age was 52.6 ± 13.3 years in the inflammatory group and 54.8 ± 12.9 years in the non-rheumatological group (P < .001). Female patients comprised 78% of the total population, with a significant gender difference between the 2 groups (P < .001). Conclusion: Nearly one-third of patients with joint pain referred to rheumatology received an inflammatory rheumatological diagnosis. These findings may inform clinical triage, improve early diagnosis, and contribute to more efficient healthcare utilization.
- Open Access
- 27 February 2026
- Published by Cukurova Medical Journal in Cukurova Medical Journal
- Vol. 51 (1) , 147-153
Evaluation of inferior vena cava wall thickness measured by transthoracic echocardiography as a marker of vascular involvement in Behçet's disease
Purpose: This study aimed to evaluate inferior vena cava diameter (IVCD) and wall thickness (IVCWT) in patients with Behçet’s disease (BD) using transthoracic echocardiography (TTE), and to investigate their associations with disease activity and vascular involvement. Materials and Methods: This prospective cross-sectional study included 79 patients diagnosed with BD and 84 age- and sex-matched healthy controls. All TTE measurements, including IVCD and IVCWT, were performed during the study period using a standardized protocol. Disease activity was assessed using the Behçet’s Disease Current Activity Form (BDCAF). Subgroup analyses were conducted based on vascular involvement and other clinical characteristics. Results: IVCWT was slightly higher in patients with BD compared with healthy controls (2.35 ± 0.52 mm vs. 2.26 ± 0.57 mm). No meaningful association was identified between disease activity scores and IVC measurements. In contrast, (2.83 ± 0.60 mm vs. 2.28 ± 0.44 mm). Intra-observer reliability was excellent for both IVCWT (ICC = 0.93) and IVC diameter (ICC = 0.91). Conclusion: Increased IVCWT measured by transthoracic echocardiography may indicate vascular involvement in BD independently of overall disease activity. Given its non-invasive nature and high reproducibility, IVCWT could serve as a supportive parameter for identifying subclinical vascular inflammation and guiding individualized follow-up strategies.
- 27 February 2026
- Published by Cukurova Medical Journal in Cukurova Medical Journal
- Vol. 51 (1) , 147-153
Open AccessEvaluation of inferior vena cava wall thickness measured by transthoracic echocardiography as a marker of vascular involvement in Behçet's disease
Purpose: This study aimed to evaluate inferior vena cava diameter (IVCD) and wall thickness (IVCWT) in patients with Behçet’s disease (BD) using transthoracic echocardiography (TTE), and to investigate their associations with disease activity and vascular involvement. Materials and Methods: This prospective cross-sectional study included 79 patients diagnosed with BD and 84 age- and sex-matched healthy controls. All TTE measurements, including IVCD and IVCWT, were performed during the study period using a standardized protocol. Disease activity was assessed using the Behçet’s Disease Current Activity Form (BDCAF). Subgroup analyses were conducted based on vascular involvement and other clinical characteristics. Results: IVCWT was slightly higher in patients with BD compared with healthy controls (2.35 ± 0.52 mm vs. 2.26 ± 0.57 mm). No meaningful association was identified between disease activity scores and IVC measurements. In contrast, (2.83 ± 0.60 mm vs. 2.28 ± 0.44 mm). Intra-observer reliability was excellent for both IVCWT (ICC = 0.93) and IVC diameter (ICC = 0.91). Conclusion: Increased IVCWT measured by transthoracic echocardiography may indicate vascular involvement in BD independently of overall disease activity. Given its non-invasive nature and high reproducibility, IVCWT could serve as a supportive parameter for identifying subclinical vascular inflammation and guiding individualized follow-up strategies.
- Open Access
- 4 June 2023
- Published by Ahi Evran Medical Journal, Kirsehir Ahi Evran University in Ahi Evran Medical Journal
- Vol. 8 (1) , 126-129
Secondary Anti-phospholipid Antibody Syndrome Due to Systemic Lupus Erythematosus: A Case Report with Superior Mesenteric Artery Involvement
Antiphospholipid antibody syndrome (APS); is a disease characterized by anti-phospholipid protein antibody positivity as well as recurrent vascular thrombosis and/or pregnancy loss. When no underlying disease is detected, it is classified as primary type; when there is another underlying rheumatologic disease, it is classified as secondary type. Secondary APS, most commonly develops due to systemic lupus erythematosus (SLE). We present a case of ischemic colitis due to superior mesenteric artery involvement in APS. 59-year-old female patient diagnosed with SLE had sudden-onset hematochezia and acute abdomen. Therefore, the patient underwent contrast-enhanced computed tomography angiography (CT angiography). Thrombosis was detected in the superior mesenteric artery. This case was interesting in terms of different vascular involvement and treatment strategy in the gastrointestinal tract due to APS.
- 4 June 2023
- Published by Ahi Evran Medical Journal, Kirsehir Ahi Evran University in Ahi Evran Medical Journal
- Vol. 8 (1) , 126-129
Open AccessSecondary Anti-phospholipid Antibody Syndrome Due to Systemic Lupus Erythematosus: A Case Report with Superior Mesenteric Artery Involvement
Antiphospholipid antibody syndrome (APS); is a disease characterized by anti-phospholipid protein antibody positivity as well as recurrent vascular thrombosis and/or pregnancy loss. When no underlying disease is detected, it is classified as primary type; when there is another underlying rheumatologic disease, it is classified as secondary type. Secondary APS, most commonly develops due to systemic lupus erythematosus (SLE). We present a case of ischemic colitis due to superior mesenteric artery involvement in APS. 59-year-old female patient diagnosed with SLE had sudden-onset hematochezia and acute abdomen. Therefore, the patient underwent contrast-enhanced computed tomography angiography (CT angiography). Thrombosis was detected in the superior mesenteric artery. This case was interesting in terms of different vascular involvement and treatment strategy in the gastrointestinal tract due to APS.
- 11 February 2022
- Published by Galenos Yayinevi in European Journal of Geriatrics and Gerontology
- Vol. 4 (1) , 26-31
Sicca Symptoms and Its Relationship with Primary Sjögren’s Syndrome in Geriatric Patients
- 11 February 2022
- Published by Galenos Yayinevi in European Journal of Geriatrics and Gerontology
- Vol. 4 (1) , 26-31
Sicca Symptoms and Its Relationship with Primary Sjögren’s Syndrome in Geriatric Patients
- Open Access
- 23 April 2021
- Published by Adiyaman University in Adıyaman Üniversitesi Sağlık Bilimleri Dergisi
- Vol. 7 (1) , 20-25
Comparison of Familial Mediterranean Fever patients by triglyceride/high-density lipoprotein ratio
Aim: In this study, we aimed to show whether there is a relationship between FMF disease and cardiovascular risk by comparing Triglyceride/HDL-Cholesterol ratios between FMF patients and the control group.Materials and Methods: A total of 300 patients, including 150 Familial Mediterranean Fever (FMF) patients and 150 control groups aged 18-65, were included in our study. Triglyceride/HDL-Cholesterol ratios of the patients were compared.Results: Triglyceride/HDL-Cholesterol ratio was statistically significantly higher in the FMF group than the control group (p=0.026).Conclusion: In FMF patients, the Triglyceride/HDL-Cholesterol ratio can be used as an inexpensive, reproducible predictor in showing a cardiac risk.
- 23 April 2021
- Published by Adiyaman University in Adıyaman Üniversitesi Sağlık Bilimleri Dergisi
- Vol. 7 (1) , 20-25
Open AccessComparison of Familial Mediterranean Fever patients by triglyceride/high-density lipoprotein ratio
Aim: In this study, we aimed to show whether there is a relationship between FMF disease and cardiovascular risk by comparing Triglyceride/HDL-Cholesterol ratios between FMF patients and the control group.Materials and Methods: A total of 300 patients, including 150 Familial Mediterranean Fever (FMF) patients and 150 control groups aged 18-65, were included in our study. Triglyceride/HDL-Cholesterol ratios of the patients were compared.Results: Triglyceride/HDL-Cholesterol ratio was statistically significantly higher in the FMF group than the control group (p=0.026).Conclusion: In FMF patients, the Triglyceride/HDL-Cholesterol ratio can be used as an inexpensive, reproducible predictor in showing a cardiac risk.
- Open Access
- 30 January 2020
- Published by Springer Nature in Advances in Rheumatology
- Vol. 60 (1) , 1-7
Assessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant/unresponsive familial Mediterranean fever
İntroduction: Familial Mediterranean fever (FMF) is a hereditary auto-inflammatory disease characterized by recurrent fever and serosal inflammation. Anti-interleukin-1 (Anti-IL-1) treatments are recommended in colchicine resistant and/or intolerant FMF patients. This study aims to evaluate the efficacy of anakinra and canakinumab in FMF patients that are resistant/intolareted to colchicine or complicated with amyloidosis. Methods: Between January 2014 and March 2019, 65 patients following-up at Sivas Cumhuriyet University (Medical Faculty Rheumatology-Internal Medicine Department) who were diagnosed with FMF according to the criteria of Tel-Hashomer were included in the study. The laboratory values and clinical features of patients and disease activities were recorded at least every 3 months, and these data were analyzed. Results: Forty-one (63.1%) patients used anakinra (100 mg/day) and 24 (36.9%) patients used canakinumab (150 mg/8 week). The median duration of anti-IL-1 agents use was 7 months (range, 3–30). Fifteen (23.1%) cases were complicated with amyloidosis. Seven (10.8%) patients had renal transplantation. Overall, the FMF 50 score response was 96.9%. In the group that had a glomerular filtration rate (GFR) ≥ 60 ml/min/m2, the median proteinuria decreased from 2390 mg/day (range, 1400–7200) to 890 mg/day (range, 120–2750) (p = 0.008). No serious infections were detected, except in one patient. Conclusions: Anti-IL-1 agents are effective and safe in the treatment of FMF patients. These agents are particularly effective at reducing proteinuria in patients with GFR ≥ 60 ml/min/m2, but less effective in cases with FMF associated with arthritis and sacroiliitis. Large and long follow-up studies are now needed to establish the long-term effects of these treatments.
- 30 January 2020
- Published by Springer Nature in Advances in Rheumatology
- Vol. 60 (1) , 1-7
Open AccessAssessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant/unresponsive familial Mediterranean fever
İntroduction: Familial Mediterranean fever (FMF) is a hereditary auto-inflammatory disease characterized by recurrent fever and serosal inflammation. Anti-interleukin-1 (Anti-IL-1) treatments are recommended in colchicine resistant and/or intolerant FMF patients. This study aims to evaluate the efficacy of anakinra and canakinumab in FMF patients that are resistant/intolareted to colchicine or complicated with amyloidosis. Methods: Between January 2014 and March 2019, 65 patients following-up at Sivas Cumhuriyet University (Medical Faculty Rheumatology-Internal Medicine Department) who were diagnosed with FMF according to the criteria of Tel-Hashomer were included in the study. The laboratory values and clinical features of patients and disease activities were recorded at least every 3 months, and these data were analyzed. Results: Forty-one (63.1%) patients used anakinra (100 mg/day) and 24 (36.9%) patients used canakinumab (150 mg/8 week). The median duration of anti-IL-1 agents use was 7 months (range, 3–30). Fifteen (23.1%) cases were complicated with amyloidosis. Seven (10.8%) patients had renal transplantation. Overall, the FMF 50 score response was 96.9%. In the group that had a glomerular filtration rate (GFR) ≥ 60 ml/min/m2, the median proteinuria decreased from 2390 mg/day (range, 1400–7200) to 890 mg/day (range, 120–2750) (p = 0.008). No serious infections were detected, except in one patient. Conclusions: Anti-IL-1 agents are effective and safe in the treatment of FMF patients. These agents are particularly effective at reducing proteinuria in patients with GFR ≥ 60 ml/min/m2, but less effective in cases with FMF associated with arthritis and sacroiliitis. Large and long follow-up studies are now needed to establish the long-term effects of these treatments.
- Open Access
- 1 January 2020
- Published by XMLink in Journal of Korean Medical Science
- Vol. 35 (10) , e63
Can Calprotectin Show Subclinical Inflammation in Familial Mediterranean Fever Patients?
Asan G, et al. J Korean Med Sci. 2020 Feb;35(10):e63. https://doi.org/10.3346/jkms.2020.35.e63
- 1 January 2020
- Published by XMLink in Journal of Korean Medical Science
- Vol. 35 (10) , e63
Open AccessCan Calprotectin Show Subclinical Inflammation in Familial Mediterranean Fever Patients?
Asan G, et al. J Korean Med Sci. 2020 Feb;35(10):e63. https://doi.org/10.3346/jkms.2020.35.e63
- 18 June 2019
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 22 (8) , 1474-1478
Low levels of pannexin‐1 in Behçet’s syndrome
Objective Behçet's syndrome (BS) is a chronic, multisystemic and inflammatory syndrome. In our study, we aimed to compare the initiator, effector and inflammatory caspases and pannexin channel protein, which is thought to have an activity in inflammation, in the inflammatory process of BS, with healthy subjects, to investigate their level in patients and their relationship with the clinical findings. Method Forty‐six patients who were under follow‐up for BS in the Sivas Cumhuriyet University Medical Faculty Department of Internal Diseases, Rheumatology Unit, between January 2017 and June 2017 and 44 healthy controls (HC) who did not have any rheumatic, systemic or metabolic diseases, were enrolled in this study. Results The mean serum pannexin‐1 level was 6.36 (4.21‐527.2) pg/mL in the BS group and 255.8 (5.38‐2000) pg/mL in the HC group. Serum pannexin‐1 levels were statistically significantly lower in the BS group (P < 0.0001). The measured mean serum caspase‐3 level was 12.04 (11.25‐43.69) pg/mL in the group with BS and 12.1 (11.19‐484.3) pg/mL in the HC group (P = 0.143), mean serum caspase‐9 level was 22 (5.14‐29.33) pg/mL in the BS group and 22.01 (11.23‐850) pg/mL in the HC group (P = 0.593), mean serum caspase‐14 level was 6 (5.2‐8.21) pg/mL in the BS group and 6.15 (5.7‐353) pg/mL in the HC group (P = 0.053). Conclusion Comparison of serum caspase‐3, caspase‐9 and caspase‐14 levels in subjects with BS and in the HC group did not reveal any statistically significant differences. On the other hand, serum pannexin‐1 levels were statistically significantly lower in the BS group.
- 18 June 2019
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 22 (8) , 1474-1478
Low levels of pannexin‐1 in Behçet’s syndrome
Objective Behçet's syndrome (BS) is a chronic, multisystemic and inflammatory syndrome. In our study, we aimed to compare the initiator, effector and inflammatory caspases and pannexin channel protein, which is thought to have an activity in inflammation, in the inflammatory process of BS, with healthy subjects, to investigate their level in patients and their relationship with the clinical findings. Method Forty‐six patients who were under follow‐up for BS in the Sivas Cumhuriyet University Medical Faculty Department of Internal Diseases, Rheumatology Unit, between January 2017 and June 2017 and 44 healthy controls (HC) who did not have any rheumatic, systemic or metabolic diseases, were enrolled in this study. Results The mean serum pannexin‐1 level was 6.36 (4.21‐527.2) pg/mL in the BS group and 255.8 (5.38‐2000) pg/mL in the HC group. Serum pannexin‐1 levels were statistically significantly lower in the BS group (P < 0.0001). The measured mean serum caspase‐3 level was 12.04 (11.25‐43.69) pg/mL in the group with BS and 12.1 (11.19‐484.3) pg/mL in the HC group (P = 0.143), mean serum caspase‐9 level was 22 (5.14‐29.33) pg/mL in the BS group and 22.01 (11.23‐850) pg/mL in the HC group (P = 0.593), mean serum caspase‐14 level was 6 (5.2‐8.21) pg/mL in the BS group and 6.15 (5.7‐353) pg/mL in the HC group (P = 0.053). Conclusion Comparison of serum caspase‐3, caspase‐9 and caspase‐14 levels in subjects with BS and in the HC group did not reveal any statistically significant differences. On the other hand, serum pannexin‐1 levels were statistically significantly lower in the BS group.